These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24883155)

  • 1. Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes.
    Kutoh E; Hirate M; Ikeno Y
    J Clin Med Res; 2014 Aug; 6(4):287-94. PubMed ID: 24883155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
    Kutoh E; Wada A; Terayama S
    Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.
    Kutoh E; Wada A; Murayama T; Hayashi J
    Drugs R D; 2018 Dec; 18(4):309-315. PubMed ID: 30324549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
    Kutoh E; Murayama T; Wada A; Hirate M
    Drugs R D; 2016 Dec; 16(4):369-376. PubMed ID: 27798769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
    Kutoh E; Wada A; Hayashi J
    Endocr Pract; 2018 Dec; 24(12):1063-1072. PubMed ID: 30289315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
    Takamiya Y; Okamura K; Shirai K; Okuda T; Kobayashi K; Urata H
    Clin Exp Hypertens; 2020; 42(3):197-204. PubMed ID: 30974980
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.
    Kim HJ; Kim YS; Lee CB; Choi MG; Chang HJ; Kim SK; Yu JM; Kim TH; Lee JH; Ahn KJ; Kim K; Lee KW
    Diabetes Ther; 2019 Aug; 10(4):1271-1282. PubMed ID: 31079357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Link between serum uric acid and pancreatic beta-cell function in drug naïve subjects with type 2 diabetes treated with sitagliptin.
    Kutoh E; Wada A; Kuto AN; Hayashi J; Kurihara R
    Hosp Pract (1995); 2021 Apr; 49(2):71-78. PubMed ID: 33191818
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study.
    Singh H; Rohilla R; Jaswal S; Singla M
    Expert Rev Endocrinol Metab; 2024; 19(1):81-87. PubMed ID: 38078453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li X; Huang X; Bai C; Qin D; Cao S; Mei Q; Ye Y; Wu J
    Front Pharmacol; 2018; 9():449. PubMed ID: 29780322
    [No Abstract]   [Full Text] [Related]  

  • 11. Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
    Kutoh E; Wada A; Murayama T; Takizawa Y
    Drugs R D; 2017 Jun; 17(2):313-320. PubMed ID: 28285448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
    Mohan V; Ramu M; Poongothai S; Kasthuri S
    J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
    Kutoh E; Ukai Y
    Endocrine; 2012 Jun; 41(3):435-41. PubMed ID: 22249941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
    Ito R; Fukui T; Hayashi T; Osamura A; Ohara M; Hara N; Higuchi A; Yamamoto T; Hirano T
    Drugs R D; 2015 Sep; 15(3):245-51. PubMed ID: 26224337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study.
    Kim HJ; Kim YS; Lee CB; Choi MG; Chang HJ; Kim SK; Yu JM; Kim TH; Lee JH; Ahn KJ; Min KW; Kyung EJ; Kim YK; Lee KW
    Diabetes Ther; 2021 Nov; 12(11):2907-2920. PubMed ID: 34536208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teneligliptin in management of type 2 diabetes mellitus.
    Sharma SK; Panneerselvam A; Singh KP; Parmar G; Gadge P; Swami OC
    Diabetes Metab Syndr Obes; 2016; 9():251-60. PubMed ID: 27574456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.